In a mouse pancreatic cancer model, inhibition of IL‐17‐stimulated NETosis has shown potent anti‐cancer effects and enhances sensitivity to ICIs (PD1, CTLA4) [61]. The gene discussed is IL17A; the disease is pancreatic neoplasm.